Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana / Romley, John


CiteScore 2018: 0.89

SCImago Journal Rank (SJR) 2018: 0.314
Source Normalized Impact per Paper (SNIP) 2018: 0.548

Online
ISSN
1558-9544
Alle Formate und Preise
Weitere Optionen …

Returns to Society from Investment in Cancer Research and Development

Amitabh Chandra
  • Korrespondenzautor
  • Precision Health Economics, 11100 Santa Monica Blvd Suite 500, Los Angeles, CA 90025, USA
  • Harvard University – Kennedy School of Government, Boston, MA, USA
  • E-Mail
  • Weitere Artikel des Autors:
  • De Gruyter OnlineGoogle Scholar
/ Joanna P. MacEwan / Avrita Campinha-Bacote / Zeba M. Khan
Online erschienen: 22.04.2015 | DOI: https://doi.org/10.1515/fhep-2014-0022

Abstract

Background: Since the start of the War on Cancer there have been enormous investments in improving oncology treatment. The return to society generated by this investment is unknown. We estimate the returns generated over the previous four decades and extrapolate future returns from current investment in cancer R&D.

Methods: Using data on cancer incidence, mortality, and treatment-specific R&D expenditures from 1973 to 2010, we used regression models and two-sided significance tests to relate investment in cancer treatment R&D to cancer mortality, by tumor type. For investment, we used a measure of the knowledge stock generated by cancer treatment R&D expenditures over the previous 25 years to capture the cumulative benefits of past innovations and advances in treatment.

Results: Investment of an additional $1 million in cervical, breast, colorectal, and prostate cancer between 1973 and 1990 was associated with a cumulative return of more than $5 million from cancer R&D by 2010. Through 2010, investment in cancer R&D was associated with average benefits in excess of costs in all but two cancers, ovarian and pancreatic. Regarding future returns, we estimated that each additional $1 million invested in cancer treatment research and development in 2010 will produce over $28 million in value over the following 50 years.

Conclusions: The return to society from spending on cancer treatment R&D is large, but varies across tumor types.

Dieser Artikel bietet Zusatzmaterial am Ende der Seite.

Keywords: cancer; research and development; social value

References

  • Aldy, J. E. and W. K. Viscusi (2008) “Adjusting the Value of a Statistical Life for Age and Cohort Effects,” Review of Economics and Statistics, 90(3):573–581.Web of ScienceCrossrefGoogle Scholar

  • Alston, J. M., M. A. Andersen, J. S. James and P. G. Pardey (2010) Persistence Pays: U.S. Agricultural Productivity Growth and the Benefits from Public R&D Spending. New York: Springer.Google Scholar

  • Citeline (2013) Trialtrove, Available from https://citeline.com/products/trialtrove, Informa PLC.Google Scholar

  • Congressional Budget Office (2005) R&D and Productivity Growth. CBO Background Paper. Washington, DC: Congress of the United States.Google Scholar

  • Feinstein, A. R., D. M. Sosin and C. K. Wells (1985) “The Will Rogers Phenomenon: Stage Migration and New Diagnostic Techniques as a Source of Misleading Statistics for Survival in Cancer,” New England Journal of Medicine, 312(25):1604–1608.CrossrefGoogle Scholar

  • Ferrara, N. (2010). “From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials-an interview with Napoleone Ferrara by Domenico Ribatti.” The International Journal of Developmental Biology, 55(4–5):383–388.Google Scholar

  • Griliches, Z. (1979) “Issues in Assessing the Contribution of Research and Development to Productivity Growth,” The Bell Journal of Economics, 10(1):92–116.CrossrefGoogle Scholar

  • Horm, J. W. and E. J. Sondik (1989) “Person-Years of Life Lost due to Cancer in the United States, 1970 and 1984,” American Journal of Public Health, 79(11):1490–1493.CrossrefPubMedGoogle Scholar

  • Howlader, N., A. M. Noone, M. Krapcho, J. Garshell, N. Neyman, S. F. Altekruse, C. L. Kosary, R. J. M. Yu, Z. Tatalovich, H. Cho, A. Mariotto, D. R. Lewis, H. S. Chen, E. J. Feuer and K. A. Cronin. (eds) (2013) SEER Cancer Statistics Review (CSR), 1975–2010. Bethesda, MD: National Cancer Institute.Google Scholar

  • Hutchison, G. B. and S. Shapiro (1968) “Lead Time Gained by Diagnostic Screening for Breast Cancer,” Journal of National Cancer Institute, 41(3):665–681.Google Scholar

  • Kanavos, P., R. Sullivan, G. Lewison, W. Schurer, S. Eckhouse and Z. Vlachopioti (2010) “The Role of Funding and Policies on Innovation in Cancer Drug Development,” ecancer, 4(164).Google Scholar

  • Kneller, R. (2010) “The Importance of New Companies for Drug Discovery: Origins of a Decade of New Drugs,” National Revolution Drug Discovery, 9(11):867–882.CrossrefGoogle Scholar

  • Lakdawalla, D. N., E. C. Sun, A. B. Jena, C. M. Reyes, D. P. Goldman and T. J. Philipson (2010) “An economic Evaluation of the War on Cancer,” Journal of Health Economics, 29(3):333–346.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Lichtenberg, F. R. (2009) “The Effect of New Cancer Drug Approvals on the Life Expectancy of American Cancer Patients, 1978–2004,” Economics of Innovation and New Technology, 18(5):407–428.CrossrefGoogle Scholar

  • Luce, B. R., J. Mauskopf, F. A. Sloan, J. Ostermann and L. C. Paramore (2006) “The Return on Investment in Health Care: From 1980 to 2000,” Value in Health, 9(3):146–156.CrossrefGoogle Scholar

  • Maruvka, Y. E., M. Tang and F. Michor (2014) “On the Validity of Using Increases in 5-Year Survival Rates to Measure Success in the Fight against Cancer,” PLoS ONE, 9(7):e83100.PubMedCrossrefWeb of ScienceGoogle Scholar

  • Mukherjee, S. (2011) The Emperor of all Maladies: A Biography of Cancer. New York: Simon and Schuster.Google Scholar

  • National Cancer Institute (1973–2010) The NCI Annual Fact Book. Retrieved November 1, 2013, from http://obf.cancer.gov/financial/factbook.htm.

  • National Cancer Institute (2013a) Interactive Budget Analysis Tool. Retrieved November 1, 2013, from http://budgettool.cancer.gov/.

  • National Cancer Institute (2014) “250 Years of Advances in Cancer.” Retrieved August 7, 2013, from http://www.cancer.gov/researchandfunding/progress/250-years-advances.

  • National Center for Health Statistics (2014) Health, United States, 2013: With Special Feature on Prescription Drugs, US Department of Health and Human Services, Centers for Disease Control and Prevention.Google Scholar

  • Pammolli, F., L. Magazzini and M. Riccaboni (2011) “The Productivity Crisis in Pharmaceutical R&D,” National Revolution Drug Discovery, 10(6):428–438.CrossrefGoogle Scholar

  • Pharmaceutical Research and Manufacturers of America (2013) Biopharmaceutical Research Industry Profile. Washington, DC: PhRMA.Google Scholar

  • Reichert, J. M. (2003) “Trends in Development and Approval Times for New Therapeutics in the United States,” National Revolution Drug Discovery, 2(9):695–702.CrossrefGoogle Scholar

  • Surveillance Epidemiology and End Results Program (1973–2011) Cancer Statistics, National Cancer Insititute.Google Scholar

  • United States Census Bureau (2013) 2015–2060 National Population Projections. Retrieved November 1, 2013, from http://www.census.gov/population/projections/data/national/2012.html.

  • United States Census Bureau (2014a) State & County QuickFacts. United States Census Bureau.Google Scholar

  • United States Census Bureau (2014b) Population. Washington, DC: United States Census Bureau.Google Scholar

  • Weinstein, M. C., J. E. Siegel, M. R. Gold, M. S. Kamlet and L. B. Russell (1996) “Recommendations of the Panel on Cost-effectiveness in Health and Medicine,” Journal of Medical Association 276(15):1253–1258.CrossrefGoogle Scholar

Artikelinformationen

Corresponding author: Amitabh Chandra, Precision Health Economics, 11100 Santa Monica Blvd Suite 500, Los Angeles, CA 90025, USA, Tel.: +310-984-7738, e-mail: amitabh.chandra@precisionhealtheconomics.com; and Harvard University – Kennedy School of Government, Boston, MA, USA


Online erschienen: 22.04.2015

Erschienen im Druck: 01.06.2016


Conflict of interest: Precision Health Economics is a consultancy to the health insurance and life science industries. AC holds the position of Chief Scientific Officer at Precision Health Economics. JPM and ACB are employees of Precision Health Economics. ZK is an employee of Celgene Corporation.

Research funding: None declared.

Author statement: This research was supported by Celgene Corporation under contract with Precision Health Economics. Precision Health Economics is a consultancy to the health insurance and life science industries. AC holds the position of Chief Scientific Officer at Precision Health Economics. JPM and ACB are employees of Precision Health Economics. ZK is an employee of Celgene Corporation.


Quellenangabe: Forum for Health Economics and Policy, Band 19, Heft 1, Seiten 71–86, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: https://doi.org/10.1515/fhep-2014-0022.

Zitat exportieren

©2016 by De Gruyter.Get Permission

Zusatzmaterial zum Artikel

Kommentare (0)